Unwarranted imaging for distant metastases in patients with newly diagnosed ductal carcinoma in situ and stage I and II breast cancer
Authors:
- 1 April 2020
- journal article
- conference paper
- Published by CMA Impact Inc. in Canadian Journal Of Surgery
- Vol. 63 (2) , E100-E109
Abstract
Background In 2012, the American Society of Clinical Oncology (ASCO) released a Choosing Wisely Top Five list that included a recommendation against ordering advanced imaging tests to screen for metastases among asymptomatic patients with early breast cancer. Our provincial breast cancer staging guideline was subsequently updated. We report on the use of unwarranted bone scanning (BS), computed tomography (CT), nonbreast magnetic resonance imaging (MRI) and positron emission tomography (PET) among women diagnosed with stage 0-II breast cancer in Alberta in 2011-2015. Methods The cohort was retrospectively ascertained from the Alberta Cancer Registry. We used additional provincial data sources to obtain information about diagnostic imaging tests completed from biopsy to surgical date plus 4 months. The reason for each BS, CT, MRI and PET was abstracted. We calculated the frequency of advanced imaging tests completed for routine metastatic screening. Results Of 10 142 patients included, 2887 (28.5%) had at least 1 advanced imaging test completed for routine metastatic screening. Of these 2887 patients, 438 (15.2%) had a follow-up BS, CT, MRI or PET, and 28 patients (1.0%) had a nonbreast image-guided biopsy. Use of routine advanced imaging tests did not change clearly over time. Conclusion Our results demonstrate persistent use of advanced imaging tests for routine metastatic screening among patients with stage 0-II breast cancer despite the release of the ASCO Choosing Wisely recommendations and the update of our provincial breast cancer staging guideline. Investigation of strategies for guideline translation to improve upon value-based care of patients with early breast cancer is warranted. Contexte En 2012, l'American Society of Clinical Oncology (ASCO) a publie sa liste de 5 interventions a << Choisir avec soin >>, dans laquelle elle recommandait notamment de ne pas recourir aux techniques d'imagerie de pointe pour le depistage des metastases chez les patientes atteintes d'un cancer du sein peu avance et asymptomatique. Nos lignes directrices provinciales pour la stadification du cancer du sein ont ete mises a jour en consequence. Nous faisons aujourd'hui etat de l'utilisation injustifiee de la scintigraphie osseuse (SO), de la tomodensitometrie (TDM), de l'imagerie par resonnance magnetique (IRM) non mammaire et de la tomographie par emission de positrons (TEP) chez les femmes ayant recu un diagnostic de cancer du sein peu avance (stade 0-II) en Alberta entre 2011 et 2015. Methodes La cohorte a ete reunie de maniere retrospective a partir du registre albertain du cancer. Nous avons utilise d'autres sources de donnees provinciales pour obtenir des renseignements sur les epreuves d'imagerie diagnostique effectuees entre les dates de la biopsie et les dates de la chirurgie plus 4 mois. Le motif invoque pour recourir a chaque SO, TDM, IRM et TEP a ete recueilli. Nous avons calcule la frequence des epreuves d'imagerie de pointe effectuees pour un depistage de routine des metastases. Resultats Sur les 10 142 patientes incluses, 2887 (28,5 %) avaient subi au moins 1 epreuve d'imagerie de pointe pour le depistage de routine des metastases. Parmi ces 2887 patientes, 438 (15,2 %) ont subi une SO, une TDM, une IRM ou une TEP de suivi et 28 patientes (1,0 %) ont subi une biopsie non mammaire guidee par l'imagerie. L'utilisation de routine des epreuves d'imagerie de pointe n'a pas nettement change avec le temps. Conclusion Selon nos resultats, l'utilisation des epreuves d'imagerie de pointe pour le depistage de routine des metastases persiste chez les patientes atteintes d'un cancer du sein de stade 0-II, malgre la publication des recommandations Choisir avec soin de l'ASCO et la mise a jour de nos lignes directrices provinciales concernant la stadification du cancer du sein. Il faudra se pencher sur des strategies pour ameliorer l'adoption de lignes directrices relatives aux soins veritablement utiles pour les patientes atteintes d'un cancer du sein peu avance.Keywords
This publication has 24 references indexed in Scilit:
- Are Physicians Choosing Wisely When Imaging for Distant Metastases in Women With Operable Breast Cancer?Journal of Oncology Practice, 2015
- Imaging for metastatic disease in patients with newly diagnosed breast cancer: are doctor's perceptions in keeping with the guidelines?Journal of Evaluation in Clinical Practice, 2014
- Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2013
- Prognostic Impact of 18FDG-PET-CT Findings in Clinical Stage III and IIB Breast CancerJNCI: Journal of the National Cancer Institute, 2012
- Advanced Imaging Modalities in Early Stage Breast Cancer: Preoperative Use in the United States Medicare PopulationAnnals of Surgical Oncology, 2012
- American Society of Clinical Oncology Identifies Five Key Opportunities to Improve Care and Reduce Costs: The Top Five List for OncologyJournal of Clinical Oncology, 2012
- Evaluation of the evidence on staging imaging for detection of asymptomatic distant metastases in newly diagnosed breast cancerThe Breast, 2012
- Use of contrast-enhanced computed tomography in clinical staging of asymptomatic breast cancer patients to detect asymptomatic distant metastasesOncology Letters, 2012
- Changes in the Use and Costs of Diagnostic Imaging Among Medicare Beneficiaries With Cancer, 1999-2006JAMA, 2010
- Baseline staging tests after a new diagnosis of breast cancer: further evidence of their limited indicationsAnnals of Oncology, 2005